Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence-0

<p><b>Copyright information:</b></p><p>Taken from "Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence"</p><p>http://www.capmh.com/content/1/1/13</p><p>Child and Adolescent Psychiatry and Mental Health 2007;1():13-13.</p><p>Published online 15 Nov 2007</p><p>PMCID:PMC2216002.</p><p></p>date; IR: immediate-release formulations (Ritalin, branded generics [Equasym, Medikinet], generics; Focalin); MR: modified-release formulations (ConcertaXL, EquasymXL, Medikinetretard, FocalinXR; MPH-Patch: transdermal system (Daytrana); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: atomoxetine (Strattera), armodafinil (Nuvigil); DEX: dexamphetamine (England only)